Impact of BRCA mutations on outcomes among patients with serous endometrial cancer

Abstract

Although not significant, BRCA mutation carriers tended to have more advanced disease at diagnosis. However, the survival was similar irrespective of the BRCA status in this small group. Further research is needed to confirm these findings in a larger cohort.

Effect of BRCA1 and BRCA2 mutations on endometrial carcinoma survival rates

“…Patients with BRCA1 and BRCA2 mutations had more favorable outcomes than noncarriers in endometrial carcinoma, which differ from the results of previous studies. There were no signi cant differences identi ed in prognosis of uterine serous carcinoma between BRCA mutation carriers and noncarriers [17]. In addition, our ndings differ from the analysis of ovarian cancer data from the Cancer Genome Atlas project, and another study that found that patients with BRCA2 mutation had more favorable prognosis than BRCA2 non-carriers [19,23].…”

“…To the best of our knowledge, this study was the rst to investigate the effect of BRCA mutations on the prognosis of endometrioid endometrial carcinoma. Patients with BRCA1 mutations presented with higher risk disease than non-carrier group and BRCA2 mutation carriers [17]. Among endometrioid endometrial carcinoma group, there were more patients with BRCA1 or BRCA2 mutation than non-carrier group in our study.…”

“…Patients with BRCA1 mutations tend to have more aggressive histology [15], higher grade [16], and more advanced stage than noncarriers [16,17]. Less data was available in BRCA2 mutated epithelial ovarian cancers and uterine serous carcinomas due to lower prevalence [15,17,18]. One small cohort identi ed that prognosis was similar in BRCA mutated uterine serous carcinoma and non-carriers [17].…”

“…Less data was available in BRCA2 mutated epithelial ovarian cancers and uterine serous carcinomas due to lower prevalence [15,17,18]. One small cohort identi ed that prognosis was similar in BRCA mutated uterine serous carcinoma and non-carriers [17]. Another study found that gBRCA1 and gBRCA2 mutation carriers were associated with favorable 5-year overall survival in epithelial ovarian cancer [19].…”

“…One study reported that BRCA2 mutation carriers have more favorable outcomes than non-carriers [23]. Less data is available for prognosis of patients with endometrial carcinomas based on BRCA1 and BRCA2 mutations status [17].…”